

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

KING DRUG COMPANY OF FLORENCE, INC., <u>et al.</u> ,	:	CIVIL ACTION
Plaintiffs,	:	
v.	:	No. 2:06-cv-1797
CEPHALON, INC., <u>et al.</u> ,	:	
Defendants.	:	
<hr/>		
VISTA HEALTHPLAN, INC., <u>et al.</u> ,	:	CIVIL ACTION
Plaintiffs,	:	
v.	:	No. 2:06-cv-1833
CEPHALON, INC., <u>et al.</u> ,	:	
Defendants.	:	
<hr/>		
APOTEX, INC.,	:	CIVIL ACTION
Plaintiff,	:	
v.	:	No. 2:06-cv-2768
CEPHALON, INC., <u>et al.</u> ,	:	
Defendants.	:	
<hr/>		

ORDER

AND NOW, this 7th day of May, 2014, upon consideration of Plaintiffs' joint unopposed "Motion for Leave to Consolidate Briefing" (06-2768, doc. no. 731), it is **ORDERED** that the motion is **GRANTED**. Apotex, the End Payor Plaintiffs, and the Direct Purchaser Plaintiffs may each file a consolidated brief, not to exceed 55 pages, responding to the three summary judgment

motions filed against them on April 4, 2014. The individual plaintiffs may file a consolidated brief, not to exceed 40 pages, opposing the April 4, 2014 motions filed by Mylan and Ranbaxy.

It is **FURTHER ORDERED** that Plaintiffs' request to cite to exhibits used in the Apotex v. Cephalon patent trial without attaching physical copies of those exhibits is **GRANTED**. Plaintiffs' shall, however, provide the Court with an electronic copy of any exhibits so cited.

BY THE COURT:

/s/ Mitchell S. Goldberg

Mitchell S. Goldberg, J.

